Protein Summary
Modulates cytoplasmic dynein binding to an organelle, and plays a role in prometaphase chromosome alignment and spindle organization during mitosis. Involved in anchoring microtubules to centrosomes. May play a role in synapse formation during brain development. This gene encodes a 50-kD subunit of dynactin, a macromolecular complex consisting of 10-11 subunits ranging in size from 22 to 150 kD. Dynactin binds to both microtubules and cytoplasmic dynein. It is involved in a diverse array of cellular functions, including ER-to-Golgi transport, the centripetal movement of lysosomes and endosomes, spindle formation, chromosome movement, nuclear positioning, and axonogenesis. This subunit is present in 4-5 copies per dynactin molecule. It contains three short alpha-helical coiled-coil domains that may mediate association with self or other dynactin subunits. It may interact directly with the largest subunit (p150) of dynactin and may affix p150 in place. Multiple alternatively spliced tran ...more
- ENST00000434715
- ENSP00000408910
- ENSG00000175203
- ENST00000543672
- ENSP00000439376
- ENST00000548249
- ENSP00000447824
- DCTN50
- RBP50
- DCTN50
- HEL-S-77
- DYNAMITIN
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
disease perturbation | 0.96 | ||
co-expressed gene | 0.85 | ||
cellular component | 0.79 | ||
transcription factor binding site profile | 0.74 | ||
hub protein | 0.71 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 87.87 (req: < 5)
Gene RIFs: 11 (req: <= 3)
Antibodies: 331 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 87.87 (req: >= 5)
Gene RIFs: 11 (req: > 3)
Antibodies: 331 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 14
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0